Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Regulatory News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.19
Bid: 0.18
Ask: 0.20
Change: 0.00 (0.00%)
Spread: 0.02 (11.111%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.19
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notification of Major Holdings

12 Feb 2020 16:10

RNS Number : 8166C
Nuformix PLC
12 February 2020
 

NTR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Nuformix Plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Alan Chorlton

City and country of registered office (if applicable)

UK

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

18/11/2019

6. Date on which issuer notified (DD/MM/YYYY):

10/02/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

34,917,413

7.12%

490,145,083

Position of previous notification (if

applicable)

42,000,000

8.57%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BYW79Y38

34,917,413

7.12%

SUBTOTAL 8. A

34,917,413

7.12%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

x

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

Wickhambrook, Newmarket, Suffolk, UK

Date of completion

10/02/2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLKKBBKABKDFBD
Date   Source Headline
19th Mar 20242:39 pmRNSResult of AGM
1st Mar 20247:00 amRNSSubscription to raise £150,000
15th Jan 202411:30 amRNSPosting of Annual Report and Notice of AGM
3rd Jan 20247:00 amRNSResults for the period ended 30 September 2023
18th Dec 20237:00 amRNSNXP001 Update
23rd Oct 20237:00 amRNSNotice of Allowance of NXP002 Patent in Japan
18th Sep 20237:00 amRNSNXP001 Update
24th Aug 20231:22 pmRNSResult of Annual General Meeting
31st Jul 20232:00 pmRNSNotice of AGM
26th Jul 20232:55 pmRNSHolding(s) in Company
2nd Jun 20237:00 amRNSInvestor Online Q&A
25th May 20237:00 amRNSChange of Auditor
22nd May 20237:00 amRNSUnaudited Interim Report
18th May 20237:00 amRNSNXP002 Inflammation and Duration of Action Update
26th Apr 202310:55 amRNSHolding(s) in Company
17th Apr 20237:00 amRNSSubscription to raise £70,000 & issue of Warrants
27th Mar 20237:00 amRNSNXP002 Update
13th Mar 20237:00 amRNSChange of Accounting Reference Date
15th Feb 20237:00 amRNSNXP002 Update
3rd Jan 20231:37 pmRNSHolding(s) in Company
20th Dec 20221:02 pmEQSNuformix hoping to 'initiate discussions with major pharma' in 2023
20th Dec 20227:00 amRNSNXP004 Update
13th Dec 20227:00 amRNSHalf-year Report
5th Dec 20227:00 amRNSResignation of Auditor
16th Nov 20228:50 amRNSHolding(s) in Company
4th Nov 20227:00 amRNSInvestor Webinar
23rd Sep 20227:00 amRNSNXP002 Update
23rd Sep 20227:00 amRNSNXP002 Update
25th Aug 20222:39 pmRNSResult of AGM
19th Aug 20228:57 amRNSHolding(s) in Company
10th Aug 20227:00 amRNSNXP002 Completion of Tolerability Studies
1st Aug 202212:13 pmRNSPosting of Annual Report and Notice of AGM
28th Jul 20227:01 amRNSBoard Changes
28th Jul 20227:00 amRNSAnnual Results for the year ended 31 March 2022
5th Jul 20227:00 amRNSNXP002 data to be presented at 2022 ERS Congress
29th Jun 20227:00 amRNSNXP004 Update
27th Jun 20227:00 amRNSNXP002 Update
20th Jun 20227:00 amRNSHolding(s) in Company
31st May 20227:00 amRNSDirectorate Change
30th May 20227:00 amRNSCorporate Update
12th Apr 20227:00 amRNSSecond tranche of Lanstead subscription shares
11th Apr 20223:54 pmRNSHolding(s) in Company
8th Apr 202211:21 amRNSHolding(s) in Company
7th Apr 20223:44 pmRNSHolding(s) in Company
5th Apr 20226:07 pmRNSHolding(s) in Company
28th Mar 20227:00 amRNSNXP004 Patent
2nd Mar 20227:00 amRNSAppointment of Dr Dan Gooding as Consultant
1st Mar 20227:00 amRNSChange of Auditor
14th Feb 20224:37 pmRNSHolding(s) in Company
8th Feb 20227:00 amRNSOxilio NXP-001 formulation development contract

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.